Accessibility Menu
Exelixis logo

Exelixis(NASDAQ) EXEL

Market Cap$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+256%
5 Year+193%
1 Year+40%
1 Month-2%
Premium Feature
Moneyball Superscore
79/100
$54.11
+0.78%
+0.42Today
After hours$53.99-$0.12 (-0.22%)
Exelixis last closing stock price
MetricPriceDate
Last closeUSD 54.082026-08-21
Exelixis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.54%USD 51.242026-08-14
1 month-1.64%USD 54.982026-07-22
3 month+7.84%USD 50.152026-05-22
Year to date+23.39%USD 43.832025-12-31
1 year+39.71%USD 38.712025-08-21
3 year+151.77%USD 21.482023-08-22
5 year+193.28%USD 18.442021-08-20
Since inception+256.08%USD 15.192000-04-11

Exelixis Financials at a Glance

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.44B

Net Income (TTM)

$860.62M

EPS (TTM)

$3.18

P/E Ratio

16.99

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$54.11

Volume

1,949,764.529

Open

$53.74

Previous Close

$54.08

Daily Range

$53.70 - $54.68

52-Week Range

$33.76 - $57.57

Estimated Earnings Date

Nov 3, 2026

EXEL News

A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
Exelixis logo

Prediction: This Stock Could Double By 2031

Prosper Junior BakinyMay 15, 2026
mqdefault - 2026-03-26T080435.868

Exelixis: A Strong Contender in the Cancer Drug Market

Motley Fool YouTubeMar 31, 2026
exelixis

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

James HalleyFeb 28, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in SPDR S&P Biotech ETF (XBI)

Rachel WarrenFeb 25, 2026
Doctor and patient in a hospital room.

Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

Prosper Junior BakinyFeb 20, 2026
Person raising two fists in the air.

2 Stocks That Could Soar This Year

Prosper Junior BakinyJan 31, 2026
Patient sitting on hospital bed.

The Ultimate Biotech Stock to Buy With $50 Right Now

Prosper Junior BakinyOct 14, 2025
Page 1

EXEL: Motley Fool Moneyball Superscore

79

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exelixis

Exelixis, Inc. makes medicines to help people fight various forms of cancer. These treatments target specific proteins that help tumors grow and spread. The company gives patients more options for treating difficult diseases.

Fighter Molecules and Targeted Therapies

  • CABOMETYX: Tablets used to treat advanced kidney, liver, and thyroid cancers; generated $570.6 million in net product revenue in the second quarter of 2026.
  • COMETRIQ: Capsule form of cabozantinib used specifically for patients with a rare type of thyroid cancer.
  • COTELLIC: Treatment for advanced melanoma used in combination with other drugs and marketed with Genentech.
  • MINNEBRO: Oral medication for high blood pressure approved for use in Japan and licensed to Daiichi Sankyo.

Expanding the Cancer-Fighting Toolkit

  • Submitted a New Drug Application to the FDA for zanzalintinib to treat colorectal cancer in December 2025.
  • Expanded the CABOMETYX label in March 2025 to include treatments for pancreatic and extra-pancreatic neuroendocrine tumors.
  • Entered a clinical development collaboration with Merck in May 2026 to supply immunotherapy for a late-stage trial.
  • Acquired clinical-stage assets through an exclusive option and license agreement with Sairopa B.V. for a new immunotherapy candidate.

Precision Medicine and Global Partnerships

The company uses internal expertise and strategic partnerships to develop antibody-drug conjugates. These medicines deliver drug payloads directly to specific cancer cells to minimize impact on healthy tissue.

Checking the Vital Signs

  • Total revenues reached $628.7 million in the second quarter of 2026, up 11% year over year.
  • Net income rose to $212.1 million during the three-month period ended June 30, 2026.
  • The company held $1.4 billion in cash and marketable securities as of June 30, 2026.
  • Management repurchased $902.2 million of common stock through two separate programs by mid-2026.
  • Research and development spending reached $212.0 million for the second quarter of 2026 to support clinical trials.

Evolution in Oncology

Exelixis has moved from a research-focused firm to a commercial oncology company with multiple approved products. Its focus on diversifying its drug portfolio through internal discovery and external partnerships drives its long-term strategy.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,077

CEO

Michael M. Morrissey, PhD

Website

www.exelixis.com

Headquarters

Alameda, CA 94502, US

EXEL Financials

Key Financial Metrics (TTM)

Gross Margin

96.48%

Operating Margin

39.88%

Net Income Margin

35.33%

Return on Equity

42.49%

Return on Capital

37.36%

Return on Assets

34.50%

Earnings Yield

5.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.78M

Volume

1.95M

Avg. Volume

2.62M

Financials (TTM)

Gross Profit

$2.35B

Operating Income

$971.51M

EBITDA

$1.04B

Operating Cash Flow

$1.18B

Capital Expenditure

-$2.64M

Free Cash Flow

$1.18B

Cash & ST Invst.

$839.39M

Total Debt

$165.93M

Exelixis Performance Analysis

Exelixis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,611,062,00012.3%
20232023-12-31USD 1,830,208,00013.6%
20242024-12-31USD 2,168,701,00018.5%
20252025-12-31USD 2,320,126,0007.0%
Exelixis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-035.2%
Q42026-01-020.2%
Q12026-04-032.0%
Q22026-07-032.9%
Exelixis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.56-21.7%
20232023-12-31USD 0.6515.1%
20242024-12-31USD 1.76172.4%
20252025-12-31USD 2.7857.7%
Exelixis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-037.7%
Q42026-01-0225.7%
Q12026-04-03-10.2%
Q22026-07-033.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$628.69M

+10.6%

Gross Profit

$608.03M

+10.8%

Gross Margin

96.71%

N/A

Market Cap

$13.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.44M

N/A

Employees

1,077

N/A

Net Income

$212.05M

+14.7%

EBITDA

$262.68M

+10.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$839.39M

+6.1%

Total Debt

$165.93M

-7.7%

Accounts Receivable

$334.61M

+14.5%

Inventory

$28.73M

+22.3%

Long Term Debt

$165.93M

-7.7%

Short Term Debt

$0.00

N/A

Return on Assets

34.50%

N/A

Return on Invested Capital

45.56%

N/A

Free Cash Flow

$309.78M

+582.2%

Operating Cash Flow

$307.74M

+528.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BMRNBioMarin Pharmaceutical Inc.
$66.70-1.45%
HALOHalozyme Therapeutics, Inc.
$108.17+1.93%
MDGLMadrigal Pharmaceuticals, Inc.
$516.74-0.45%
ALGNAlign Technology, Inc.
$162.55+2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About EXEL

What is the current price of Exelixis?

Exelixis is trading at $54.08 per share.

What is the 52-week range for Exelixis?

Over the past 52 weeks, Exelixis has traded between $33.76 and $57.57.

How much debt does Exelixis have?

As of the most recent reporting period, Exelixis reported total debt of $165.93M.

How much cash does Exelixis have on hand?

Exelixis reported $225.56M in cash and cash equivalents in its most recent financial results.

What is Exelixis’s dividend yield?

Exelixis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services